The use of Cetirizine and Levocetirizine in patients with chronic urticaria and other allergic dermatoses: issues of dosage increasing and long-term use. Resolution of the Advisory Board

Cover Page

Cite item

Full Text

Abstract

This article reflects the main issues discussed at the Advisory Board with the participation of leading dermatovenereologists, allergists, and immunologists. The Advisory Board has become a platform for discussing the accumulated clinical and organizational problems in the field of managing patients with chronic urticaria and other allergic dermatoses. The Advisory Board also discussed the possibility of long-term use of cetirizine and levocetirizine and the use of their high doses in clinical practice. The subject of discussion was the question of the algorithm for escalation and subsequent de-escalation of the dose of non-sedating H1 antihistamines. An algorithm for escalation and de-escalation of doses of antihistamines was created based on the discussion, which can be recommended for use in clinical practice.

This article was simultaneously published in several journals with permission from authors and publishers. The parallel publication is available here: The use of cetirizine and levocetirizine in patients with chronic urticaria and other allergic dermatoses: Issues of dosage increasing and long-term use from the resolution of the Advisory Board. Effective Pharmacotherapy. 2022;18(25):6–14. DOI: https://doi.org/10.33978/2307-3586-2022-18-25-6-14. This article published with permission from authors and copyright holder.

About the authors

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
SPIN-code: 1107-4372

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Andrey N. Lvov

Central State Medical Academy of Department of Presidential Affairs; Lomonosov Moscow State University

Email: alvov@mail.ru
ORCID iD: 0000-0002-3875-4030
SPIN-code: 1053-3290

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow

Elena R. Araviyskaya

Academician I.P. Pavlov First St. Petersburg State Medical University; Galaktika Beauty Institute

Email: arelenar@mail.ru
ORCID iD: 0000-0002-6378-8582
SPIN-code: 9094-9688

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg; Saint Petersburg

Andrey L. Bakulev

Central State Medical Academy of Department of Presidential Affairs

Email: al_ba05@mail.ru
ORCID iD: 0000-0002-1450-4942
SPIN-code: 6708-7386

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Aida G. Gadzhigoroeva

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology; Institute of Beautiful Hair

Email: aida2010@mail.ru
ORCID iD: 0000-0003-0489-0576

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow

Elena S. Galimova

Bashkir State Medical University

Email: lenagalimova@mail.ru
ORCID iD: 0000-0002-3788-2284
SPIN-code: 4195-9876

MD, Dr. Sci. (Med.), Professor

Russian Federation, Ufa

Inna V. Danilychevа

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Olga G. Elisyutina

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci. (Med.), Leading Researcher

Russian Federation, Moscow

Oleg R. Ziganshin

South-Ural State Medical University; Chelyabinsk Regional Clinical Skin and Venereological Dispensary

Email: ziganshin_oleg@mail.ru
ORCID iD: 0000-0002-5857-0319
SPIN-code: 5339-2533

MD, Dr. Sci. (Med.), Professor

Russian Federation, Chelyabinsk; Chelyabinsk

Natalia I. Ilina

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov; The Russian National Research Medical University named after N.I. Pirogov

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow; Moscow

Muza M. Kokhan

Ural Research Institute of Dermatovenereology and Immunopathology

Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
SPIN-code: 3470-9306

MD, Dr. Sci (Med.), Professor

Russian Federation, Ekaterinburg

Elena V. Matushevskaya

Academy of Postgraduate Education under the Federal state budgetary institution «Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency»

Email: matushevskaya@mail.ru
ORCID iD: 0000-0003-4583-0617
SPIN-code: 7430-2112

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Natalia B. Migacheva

Samara State Medical University; Samara Regional Clinical Hospital named after V.D. Seredavin

Email: nbmigacheva@gmail.com
ORCID iD: 0000-0003-0941-9871
SPIN-code: 1313-9021

MD, Dr. Sci. (Med.), Professor

Russian Federation, Samara; Samara

Nikolay N. Murashkin

National Medical Research Center for Children’s Health

Email: m_nn2001@mail.ru
ORCID iD: 0000-0003-2252-8570
SPIN-code: 5906-9724

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Olga B. Nemchaninova

Novosibirsk State Medical University

Email: obnemchaninova@mail.ru
ORCID iD: 0000-0002-5961-6980
SPIN-code: 5658-9359

MD, Dr. Sci. (Med.), Professor

Russian Federation, Novosibirsk

Natalia M. Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Olga Yu. Olisova

First Sechenov Moscow State Medical University (Sechenov University)

Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Elena B. Pavlinova

Omsk State Medical University

Email: 123elena@mail.ru
ORCID iD: 0000-0002-6444-1871
SPIN-code: 3129-9420

MD, Dr. Sci. (Med.), Professor

Russian Federation, Omsk

Olga A. Pritulo

Medical Academy named after S.I. Georgievsky of V.I. Vernadsky Crimean Federal University

Email: 55550256@mail.ru
ORCID iD: 0000-0001-6515-1924
SPIN-code: 2988-8463

MD, Dr. Sci. (Med.), Professor

Russian Federation, Simferopol

Marina N. Repetskaya

Perm State Medical University

Email: proffrep@yandex.ru
ORCID iD: 0000-0002-2001-4296
SPIN-code: 4293-6683

MD, Dr. Sci. (Med.), Professor

Russian Federation, Perm

Alexey V. Samtsov

Military medical academy of S.M. Kirov

Email: avsamtsov@mail.ru
SPIN-code: 2287-5062

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Olga A. Sidorenko

Rostov State Medical University

Email: ola_ps@mail.ru
ORCID iD: 0000-0002-7387-2497
SPIN-code: 2209-0521

MD, Dr. Sci. (Med.), Professor

Russian Federation, Rostov-on-Don

Elena S. Snarskaya

First Sechenov Moscow State Medical University (Sechenov University)

Email: snarskaya-dok@mail.ru
ORCID iD: 0000-0002-7968-7663
SPIN-code: 3785-7859

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Evgeny V. Sokolovskiy

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: s40@mail.ru
ORCID iD: 0000-0001-7610-6061
SPIN-code: 6807-7137

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Olga B. Tamrazova

Peoples’ Friendship University of Russia

Email: anait_tamrazova@mail.ru
ORCID iD: 0000-0003-3261-6718
SPIN-code: 5476-8497

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Natalia S. Tataurshchikova

Peoples’ Friendship University of Russia

Email: natalytataur@yandex.ru
ORCID iD: 0000-0002-3486-8188
SPIN-code: 4992-3581

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Elena S. Fedenko

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Natalia V. Fedotova

Scientific Research Institute ― Ochapovsky Regional Clinic Hospital

Email: nfedotova23@mail.ru
ORCID iD: 0000-0003-0631-7212
SPIN-code: 2002-2618

MD, Cand. Sci. (Med.)

Russian Federation, Krasnodar

Natalia V. Shartanova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: nshartanova@yandex.ru
ORCID iD: 0000-0002-1197-9002
SPIN-code: 6483-8901

MD, Dr. Sci. (Med.)

Russian Federation, Moscow

Luiza A. Yusupova

Kazan State Medical Academy under the Russian Medical Academy of Continuous Professional Education

Email: yuluizadoc@hotmail.com
ORCID iD: 0000-0001-8937-2158
SPIN-code: 5743-6872

MD, Dr. Sci. (Med.), Professor

Russian Federation, Kazan

References

  1. Holgate ST, Canonica GW, Simons FE. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003;33:1305–1324. doi: 10.1046/j.1365-2222.2003.01769.x
  2. Levina YuG, Namazova-Baranova LS, Alekseeva AA, et al. Clinical and pharmacological features of the use of cetirizine in the treatment of allergic diseases in children. Pediatric Pharmacol. 2014;11(3):20–26. (In Russ).
  3. Tataurshchikova NS, Sepiashvili RI. Rational use of antihistamines in clinical practice. Educational and methodical manual. Moscow: MEDpress-inform; 2013. P. 36. (In Russ).
  4. Nettis E, Foti C, Ambrifi M, et al. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clin Mol Allergy. 2020;18:8. doi: 10.1186/s12948-020-00123-8
  5. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45:101. doi: 10.1186/s13052-019-0695-x
  6. Ansotegui IJ, Bernstein JA, Canonica GW, et al. Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride. Allergy Asthma Clin Immunol. 2022;18:41. doi: 10.1186/s13223-022-00677-z
  7. Church MK, Maurer M, Simons FE, et al.; Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459−466. doi: 10.1111/j.1398-9995.2009.02325.x
  8. Ashenager MS, Grgela T, Aragane Y, Kawada A. Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. Inv Allergol Clin Immunol. 2007;17(1):20–26.
  9. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393−1414. doi: 10.1111/all.13397
  10. Urticaria. Clinical recommendations. Russian Society of Allergologists and Clinical Immunologists, Russian Society of Dermatovenerologists and Cosmetologists, Union of Pediatricians of Russia; 2019. 60 p. (In Russ).
  11. Atopic dermatitis. Clinical recommendations. Russian Society of Dermatovenerologists and Cosmetologists, Russian Association of Allergologists and Clinical Immunologists, Union of Pediatricians of Russia; 2020. 81 p. (In Russ).
  12. Jáuregui I, Ferrer M, Montoro J, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17(Suppl. 2):41−52.
  13. Filatova TA, Revyakina VA, Kondyurina EG, Zelenskaya VV. Cetirizine (Parlazine) in the treatment of atopic dermatitis in children. Current Pediatrics. 2005;4(2):109−112. (In Russ).
  14. Ningombam A, Handa S, Srivastava N, et al. Addition of oral fexofenadine to topical therapy leads to a significantly greater reduction in the serum interleukin-31 levels in mild to moderate paediatric atopic dermatitis. Clin Exp Dermatol. 2022;47(4):724−729. doi: 10.1111/ced.15032
  15. Gillard M, Christophe B, Wels B, et al. H1 antagonists: receptor affinity versus selectivity. Inflamm Res. 2003;52(Suppl. 1):S49−50. doi: 10.1007/s000110300050
  16. Gushchin IS. Multifunctional antiallergic capabilities of the H1-receptor antagonist levocetirizine. Russian Journal of Allergy. 2014;(2):11−24. (In Russ).
  17. Corsico AG, Leonardi S, Licari A, et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidiscip Respir Med. 2019;14:40. doi: 10.1186/s40248-019-0203-6
  18. Gushchin IS. Antihistamines. Moscow: Aventis Pharma; 2000. 54 p. (In Russ).
  19. Guevara-Gutierrez E, Bonilla-Lopez S, Hernández-Arana S, Tlacuilo-Parra A. Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: double-blind randomized placebo-controlled study. J Dermatolog Treat. 2015;26(6):548−550. doi: 10.3109/09546634.2015.1025031
  20. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat. 2004;15(1):55−57. doi: 10.1080/09546630310013450
  21. Fadel R, Ramboer I, Chatterjee N, et al. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Allergy. 2000;55(9):888−891. doi: 10.1034/j.1398-9995.2000.00322.x
  22. Gushchin IS. Cetirizine ― etalon H1-antihistamine. Drugs and Technologies. 2009;(5):60−70. (In Russ).
  23. Fadel R, David B, Herpin-Richard N, et al. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating-factor (PAF-acether) in man. J Allergy Clin Immunol. 1990;86:314−320.
  24. Purohit A, Duvernelle C, Melac M, et al. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol. 2001;86(4):387−392. doi: 10.1016/S1081-1206(10)62483-0
  25. Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol. 2004;92(6):635−640. doi: 10.1016/S1081-1206(10)61429-9
  26. Sanchez J, Zakzuk J, Cardona R. Prediction of the efficacy of antihistamines in chronic spontaneous Urticaria based on initial suppression of the histamine- induced wheal. J Investig Allergol Clin Immunol. 2016;26:177–184. doi: 10.18176/jiaci.0039
  27. Kruglova LS, Tataurshchikova NS, Tipaeva EV. Issues of long-term use of antihistamines. Pharmateca. 2021;28(14):87−93. (In Russ). doi: 10.18565/pharmateca.2021.14.87-93
  28. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88(2):190−197. doi: 10.1016/S1081-1206(10)61995-3
  29. Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011;4(3 Suppl.): S22−27. doi: 10.1097/WOX.0b013e3181f385d9
  30. Kawauchi H, Yanai K, Wang DY, et al. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20:213. doi: 10.3390/ijms20010213
  31. Potter PC, Kapp A, Maurer M, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009;64:596−604. doi: 10.1111/j.1398-9995.2008.01893.x
  32. Dr. Reddy’s Laboratories [Internet]. Instructions for the medical use of the drug Allergen. LP-004008-011216. (In Russ). Available from: https://allerway.ru/instruction/allerway/. Accessed: 15.07.2022.
  33. Dr. Reddy’s Laboratories [Internet]. Instructions for the medical use of the drug Allergen Express. LP-006153. (In Russ). Available from: https://allerway.ru/instruction/allerway-express/. Accessed: 15.07.2022.
  34. Kareva EN. The choice of an antihistamine drug: a pharmacologist’s view. Russ Med J. 2016;(3):811–816. (In Russ).
  35. Dr. Reddy’s Laboratories [Internet]. Instructions for the medical use of the drug Cetrin. Р N013283/01. (In Russ). Available from: https://cetrine.ru/instrukciya. Accessed: 15.07.2022.
  36. Elisyutina OG, Fedenko ES. Experience of using cetirizine in atopic dermatitis. Russian Journal of Allergy. 2007;(5):59−62. (In Russ).
  37. State Register of Medicines. (In Russ). Available from: https://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.07.2022.
  38. Nenasheva NM, Shartanova NV, Ovchinnikov AYu, et al. Seasonal allergic rhinitis and its control with antihistamines in outpatient practice. Russian Journal of Allergy. 2020;17(2):44−52. (In Russ). doi: 10.36691/RJA1370
  39. Bachert C, Bousquet J, Canonica GW, et al.; XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):838–844. doi: 10.1016/j.jaci.2004.05.070
  40. Simons FE; Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol. 2007;18(6):535–542. doi: 10.1111/j.1399-3038.2007.00558.x
  41. Diepgen TL; Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002;13(4):278–286. doi: 10.1034/j.1399-3038.2002.01047.x
  42. Hussein Z, Pitsiu M, Majid O, et al.; ETAC Study Group. Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. Br J Clin Pharmacol. 2005;59(1):28–37. doi: 10.1111/j.1365-2125.2005.02242.x
  43. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/ GA2LEN/EDF guideline: management of urticaria. Allergy. 2006;61:321–331. doi: 10.1111/j.1398-9995.2005.00962.x
  44. Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatolog Treat. 2013;24(2):153−160. doi: 10.3109/09546634.2011.608783
  45. Zuberbier T, Aberer W, Burtin B, et al. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol. 1995;75(2):147−149. doi: 10.2340/0001555575147149
  46. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011;12(4):259−270. doi: 10.2165/11588890-000000000-00000
  47. Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. ITCH. 2020;5(4):42. doi: 10.1097/itx.0000000000000042
  48. Prurigo. Clinical recommendations. Russian Society of Dermatovenerologists and Cosmetologists. (In Russ). Available from: https://diseases.medelement.com/disease/пруриго-рекомендации-рф/15250. Accessed: 15.07.2022.
  49. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. Am Acad Allergy Asthma Immunol. 2010;125(3):676−682. doi: 10.1016/j.jaci.2009.11.047
  50. Sharma VK, Gupta V, Pathak M, Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J Dermatolog Treat. 2017;28(6):539−543. doi: 10.1080/09546634.2016.1246705
  51. Godse KV. Updosing of antihistamines to improve control of chronic urticaria. Indian J Dermatol Venereol Leprol. 2010;76(1):61−62. doi: 10.4103/0378-6323.58684
  52. Huang X, Li Z, Sun R. High-dose levocetirizine for the treatment of refractory chronic spontaneous urticaria and the effect on the serum inositol triphosphate level. J Int Med Res. 2019;47(9):4374−4379. doi: 10.1177/0300060519857768
  53. Hulhoven R, Rosillon D, Letiexhe M, et al. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007;63:1011–1017. doi: 10.1007/s00228-007-0366-5

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Algorithm of dose escalation of second generation antihistaminics.Note: UAS 7 (Urticaria Activity Score 7) index of activity of spontaneous urticaria to assess the severity of the disease and the results of treatment.

Download (748KB)
Indexing metadata
3. Fig. 2. Algorithm of dose deescalation of second generation antihistaminics.Note: A multiple dose of ns H1-AHP is divided into two doses during the day (morning and evening).

Download (683KB)
Indexing metadata

Copyright (c) 2022 Pharmarus Print Media

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».